DISP-03. FEMALE-SPECIFIC CANCER METASTASES TO THE BRAIN: OUTCOMES IN A MEDICALLY UNDERSERVED AREA. (14th November 2022)

• Record Type: Journal Article
• Authors: Shaffer, Annabelle; Krist, David; Smith, Emily; Naik, Anant; Mittal, Anisha; Smith, Alexander; Janbahan, Mika; Najafali, Daniel; Hassaneen, Wael
• Is Part Of: Neuro-oncology. Volume 24(2022)Supplement 7
• Page Start: vii127
• Page End: vii127
• Publication Date: 2022-11-14
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noac209.485
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: INTRODUCTION: Cancer care in medically underserved areas (MUA) is challenging and not widely reported. This report seeks to characterize the outcomes of female patients with brain metastases from breast, ovarian, cervical, and endometrial cancer who underwent surgical resection in an MUA. METHODS: Our institution's electronic medical record was queried for patients who underwent a craniotomy from 2013-2022. All female patients with brain metastasis from breast, ovarian, cervical, or endometrial cancer were included. The following variables were collected: alive or deceased, survival time, demographics, past medical history, metastasis location and number, extent of resection, time to metastasis, and time to recurrence. MUA was defined by the Health Resources & Services Administration's database (data.hrsa.gov). RESULTS: Nine patients had metastases from breast, four from endometrial, one from ovarian, and one from cervical cancers. Metastases were most commonly located in the posterior fossa. The median age at surgery was 65 years. The median time from primary cancer diagnosis to brain metastasis diagnosis was 2.1 years. Gross total resection (GTR) was achieved in 15/21 metastases. Recurrence occurred in 7/15 patients after a median of 10 months. At the conclusion of the study, eight patients were deceased (53%), two patients were alive with no known new metastases (13%), four were alive with new metastases (27%), and one (6.7%) was lost to follow-up. In patients who died during the study, the median survival was 9.4 months, the median age at death was 65.7 years, and 7/8 had GTR of the metastasis(es). CONCLUSION: To our knowledge, this is the first report of female-specific cancer brain metastases in an MUA. The median survival time was approximately nine months, which is similar to survival reported in multi-center studies. Further studies are recommended to identify and manage cancer care disparities in MUAs.